EPRX Eupraxia Pharma: Forward Price-to-Revenue Multiple

Corporate emblem and logo of Eupraxia Pharmaceuticals (EPRX)

The forward P/S metric demonstrates the market valuation of Eupraxia Pharmaceuticals (EPRX), where the value of 0.00 expresses the metric level. This trend is supported by a staff of leading scientists in the field of drug prolongation and the outsourcing of batch production to external plants while maintaining control over microsphere technology. High growth potential is driven by low costs for the mass production of patented suspensions following the R&D phase.

EPRX Eupraxia Pharmaceuticals, Inc.: Future Price to Revenue in the range 04/06/2024 - 04/06/2024

Metric breakdowns and analytics for Eupraxia Pharma (EPRX)

Fundamental company valuation:Eupraxia Pharmaceuticals, Inc. EPRX
Product sample of Eupraxia Pharmaceuticals, Inc.

This indicator determines the market value of Eupraxia Pharmaceuticals (EPRX) relative to projected annual sales volume, allowing investors to perform a real-time assessment of whether the premium for future growth is justified. By analyzing the current forward P/S level, it can be confirmed that the unique DiffusX platform creates a foundation for high margins and stable cash flows, which fundamentally supports the company's current market valuation.

Analysis of competing companies

Forward P/S Multiple HLN (Haleon PLC)|Forward P/S Multiple Kenvue Corp KVUE|Verona Pharma PLC - Forward P/S Multiple|Market Cap to Future Revenue Ratio jyongbio.com|LGND: Forward P/S Multiple|Market Cap to Projected Revenue AMRX|Price-to-Projected Revenue Ratio Perrigo Company|Market Cap to Future Revenue Ratio Alvotech ALVO|Forward P/S Multiple LQDA|GLPG: Future Price to Revenue|Forward P/S Multiple ANIP (ANI Pharmaceuticals, Inc.)|Market Cap to Expected Sales Ratio MannKind Corp (MNKD)|AMPH: Forward Price-to-Revenue Multiple|Forward Price to Sales PCRX (Pacira)|ARS Pharmaceuticals (SPRY) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue TBPH|AQST (Aquestive Corp) - Forward P/S Multiple|Forward Price-to-Revenue Multiple scPharmaceuticals Inc. (SCPH)|Forward Price-to-Revenue Multiple TECX (Tectonic Therapeutic, Inc.)|TNXP (Tonix Pharmaceuticals Holding) - Forward Price to Sales|Price-to-Projected Revenue Ratio SXT Pharmaceuticals SXTC|Forward Price to Sales BHST|Invizyne Technologies - Forward P/S Multiple|oramed.com (ORMP) - Forward Price-to-Revenue Multiple|ENTX (enterabio.com) - Forward Price-to-Revenue Multiple|Market Cap to Projected Revenue HYFT|ABVC (ABVC BioPharma, Inc) - Forward P/S Multiple|Forward P/S Multiple cumberlandpharma.com|Price-to-Projected Revenue Ratio Quantum BioPharma (QNTM)|FibroGen (FGEN) - Projected Price to Revenue|Forward P/S Multiple TELO (telomirpharma.com)|RANI - Forward Price-to-Revenue Multiple|SNYR - Price-to-Projected Revenue Ratio|rallybio.com - Price to Expected Revenue Ratio|LEXX: Forward P/S Multiple|Forward Price-to-Revenue Multiple Pulmatrix Inc|PTHL (Pheton Holdings) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Aptorum Group Limited APM|Price-to-Projected Revenue Ratio Lyra Therapeutics (LYRA)|Forward Price-to-Revenue Multiple Impact BioMedical Inc IBO|Price-to-Projected Revenue Ratio tnfpharma.com TNFA|Forward Price to Sales YCBD|PainReform Ltd - Forward P/S Multiple|Altamira Therapeutics Ltd (CYTO) - Forward Price-to-Revenue Multiple|lipella.com (LIPO) - Price-to-Projected Revenue Ratio|OptiNose (OPTN) - Forward P/S Multiple|PIRS (Pieris Pharmaceuticals Inc) - Forward P/S Multiple|PROC: Forward Price to Sales|Price-to-Projected Revenue Ratio Petros Pharmaceuticals, Inc. (PTPI)|Forward P/S Multiple Qilian International Corp (QLI)|ACELYRIN, Inc. - Forward Price-to-Revenue Multiple|Forward P/S Multiple tffpharma.com TFFP